Vaxart re­ports mixed PhII da­ta for norovirus vac­cine; J&J to pro­ceed with Cidara in­fluen­za deal 

Vaxart an­nounced on Wednes­day that a Phase II study of its oral norovirus vac­cine achieved the pri­ma­ry end­point of re­duc­ing the rate of in­fec­tion. The vac­cine is de­signed to go af­ter the norovirus GI.1 geno­type, which caus­es gas­troen­teri­tis.

How­ev­er, in the tri­al’s oth­er pri­ma­ry end­point, the vac­cine achieved a 21% re­duc­tion in norovirus acute gas­troen­teri­tis, which was not sta­tis­ti­cal­ly sig­nif­i­cant against the place­bo. Vaxart is plan­ning to an­a­lyze the Phase II da­ta fur­ther. — Tyler Patchen

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER